Epitinib(Synonyms: HMPL-813)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Epitinib (Synonyms: HMPL-813)

Epitinib 是一种具有口服活性和选择性的< b>表皮生长因子受体酪氨酸激酶 抑制剂 (EGFR-TKI)，可以透过血脑屏障。Epitinib 可用于癌症研究。

Epitinib(Synonyms: HMPL-813)

Epitinib Chemical Structure

CAS No. : 1203902-67-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Epitinib 的其他形式现货产品:

Epitinib succinate

生物活性

Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer[1][2].

IC50 & Target

EGFR[2]
Clinical Trial

分子量

430.50

Formula

C24H26N6O2
CAS 号

1203902-67-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhou et al. The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis. Journal of Clinical Oncology 2016 34:15_suppl, e20502-e20502

    [2]. Zhou et al. Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 2013 31:15_suppl, e19042-e19042

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务